Publication records in major medical journals such as JAMA, The Lancet, or NEJM

JAMA Study Links Bayer and AbbVie's Hormonal IUDs to Increased Breast Cancer Risk

Oct 16, 2024, 04:00 PM

A recent cohort study published in JAMA on Monday has found an association between the use of levonorgestrel-releasing intrauterine systems (IUDs) and an increased risk of breast cancer in females aged 15 to 49 years. The study indicates that while the risk remains low overall, it is higher compared to nonuse. Bayer, a dominant player in the hormonal IUD market with products such as Kyleena, Mirena, and Skyla, could be significantly impacted by these findings. AbbVie, which produces the IUD Liletta, is also mentioned in the context of this research. This study raises concerns about the safety of hormonal birth control devices used by millions of women worldwide.